

# **Thyroid cancer: assessment and management**

**[M] Evidence review for thyroid stimulating hormone (TSH) suppression versus no TSH suppression**

*NICE guideline NG230*

*Evidence reviews underpinning recommendations 1.4.1 to 1.4.5  
in the NICE guideline*

*December 2022*

*Final*



---

## **Disclaimer**

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

## **Copyright**

© NICE 2022. All rights reserved. Subject to [Notice of rights](#).

ISBN: 978-1-4731-4872-7

---

# Contents

|          |  |           |
|----------|--|-----------|
| <b>1</b> | <b>TSH suppression vs no TSH suppression.....</b>  | <b>5</b>  |
| 1.1      | Review question.....   | 5         |
| 1.1.1    | What is the clinical and cost effectiveness of TSH suppression versus no TSH suppression in different population groups, characterised by recurrence risk, ethnicity, gender and age?..... | 5         |
| 1.1.2    | Introduction.....  | 5         |
| 1.1.3    | Summary of the protocol.....   | 5         |
| 1.1.4    | Methods and process.....   | 6         |
| 1.1.5    | Effectiveness evidence.....  | 6         |
| 1.1.6    | Summary of studies included in the effectiveness evidence.....   | 7         |
| 1.1.7    | Summary of the effectiveness evidence.....   | 8         |
| 1.1.8    | Economic evidence.....   | 9         |
| 1.1.9    | Summary of included economic evidence.....   | 9         |
| 1.1.10   | Economic model.....  | 9         |
| 1.1.11   | Cost-consequence analysis.....   | 9         |
| 1.1.12   | Economic evidence statements.....  | 11        |
| 1.1.13   | The committee’s discussion and interpretation of the evidence.....   | 11        |
| 1.1.14   | Recommendations supported by this evidence review.....   | 14        |
|          | <b>References.....</b>   | <b>15</b> |
|          | <b>Appendices.....</b>   | <b>19</b> |
|          | Appendix A – Review protocols.....   | 19        |
|          | Appendix B – Literature search strategies.....   | 31        |
|          | Appendix C – Effectiveness evidence study selection.....   | 41        |
|          | Appendix D – Effectiveness evidence.....   | 42        |
|          | Appendix E – Forest plots.....   | 45        |
|          | Appendix F – GRADE tables.....   | 46        |
|          | Appendix G – Economic evidence study selection.....  | 47        |
|          | Appendix H – Economic evidence tables.....   | 48        |
|          | Appendix I – Excluded studies.....   | 49        |

# 1 TSH suppression vs no TSH suppression

## 1.1 Review question

### 1.1.1 What is the clinical and cost effectiveness of TSH suppression versus no TSH suppression in different population groups, characterised by recurrence risk, ethnicity, gender and age?

### 1.1.2 Introduction

TSH suppression with supraphysiological doses of levothyroxine has been employed in the treatment of thyroid cancer for many years. It is aimed at inhibiting the stimulatory effect of TSH on any residual thyroid cancer cells persisting after surgery and radioiodine ablation. This approach, whilst potentially reducing the risk of recurrence or progression is not without long term adverse effects. These include an increased risk of cardiovascular morbidity and mortality as well as a higher incidence of osteoporosis and fractures.

In recent years it has been proposed that TSH suppression therapy may be of little benefit and potentially harmful in certain patient groups. This review seeks to determine those patient groups who are most suitable for TSH suppression.

### 1.1.3 Summary of the protocol

For full details see the review protocol in Appendix A.

**Table 1: PICO characteristics of review question**

|                        |   |
|------------------------|---|
| <b>Population</b>      | Inclusion:<br>People aged 16 or over who have had thyroidectomy and RAI for differentiated thyroid cancer. People will need to have had total or near total thyroidectomy.<br>Exclusion:<br>Children under 16   |
| <b>Intervention(s)</b> | TSH suppression (using high doses of levothyroxine [T4] or other TSH-lowering agents, such as 'armour thyroid' [T4 + liothyronine] or liothyronine alone)   |
| <b>Comparison(s)</b>   | No TSH suppression.<br>(Note that patients, in the absence of functioning thyroid tissue, will still receive levothyroxine doses sufficient to prevent hypothyroidism, although unless actual TSH suppression is indicated the doses will not be sufficient to reduce TSH levels below normal levels)   |
| <b>Outcomes</b>        | All outcomes are considered equally important for decision making and therefore have all been rated as critical: <ul style="list-style-type: none"> <li>• mortality</li> <li>• quality of life (any validated tools)</li> <li>• thyroglobulin levels</li> <li>• local cancer progression</li> <li>• incidence of distant metastases</li> <li>• cancer recurrence</li> <li>• osteoporosis</li> <li>• cardiac complications (reported or composite outcomes allowed)</li> <li>• second primary malignancy</li> <li>• time of follow up: longest available but minimum of 3 years</li> </ul> |
| <b>Study design</b>    | <ul style="list-style-type: none"> <li>• Systematic reviews</li> <li>• RCTs</li> </ul>  |

#### **1.1.4 Methods and process**

This evidence review was developed using the methods and process described in [Developing NICE guidelines: the manual](#). Methods specific to this review question are described in the review protocol in appendix A and the methods document.

Declarations of interest were recorded according to [NICE's conflicts of interest policy](#).

#### **1.1.5 Effectiveness evidence**

##### **1.1.5.1 Included studies**

One randomised study was included in the review.<sup>1</sup> The characteristics of this study are summarised in Table 2, and evidence from this study is summarised in the clinical evidence summary in Table 3.

The included study compared TSH suppression with Levothyroxine to no additional suppression (to maintain TSH levels at a normal range). This study was put into the high risk stratum as the majority of the population were at high risk of recurrence according to the AMES assessment.

See also the study selection flow chart in Appendix C, study evidence tables in Appendix D, forest plots in Appendix E and GRADE tables in Appendix F.

##### **1.1.5.2 Excluded studies**

See the excluded studies list in Appendix I.

### 1.1.6 Summary of studies included in the effectiveness evidence

**Table 2: Summary of studies included in the evidence review**

| Study                      | Intervention and comparison  | Population  | Outcomes   | Comments   |
|----------------------------|--|---|--|--|
| Abo-Touk 2015 <sup>1</sup> | <p>Levothyroxine TSH suppression (T4): L-T4 was given at an initial dose of 100µg/d for patients with body weight under 50kg, 150 µg/d for patients weighting 50-70kg and 200µg/d for patients weighing 70kg or more. Serum levels of free T4, free T3 and TSH were done every 4 weeks. The daily dose of LT4 is then adjusted in the patients of this group to suppression TSH levels below 0.1µU/ml.<br/>(n=76)</p> <p>No additional TSH suppression: TSH suppression therapy - L-T4 was given at an initial dose of 100µg/d for patients with body weight under 50kg, 150 µg/d for patients weighting 50-70kg and 200µg/d for patients weighing 70kg or more. Serum levels of free T4, free T3 and TSH were done every 4 weeks. The daily dose of LT4 is then adjusted in the patients of this group to normal range (0.27 - 4.2 µU/ml).<br/>(n=72)</p> | <p>Patients aged from 18 - 70 with operable differentiated thyroid carcinoma</p> <p>Age<br/>&lt;45: 96;<br/>≥45: 52.</p> <p>Gender (M:F): 30/118</p> <p>T4 suppression:<br/>Ames risk of recurrence:<br/>Low - 26; high – 50</p> <p>No additional suppression:<br/>Ames risk of recurrence:<br/>low - 30; high – 42<br/>Egypt</p> | <ul style="list-style-type: none"> <li>• Cancer recurrence</li> <li>• Mortality</li> </ul> | <p>Postoperatively radioiodine therapy was given when the patient with a completely resected tumour had a significant potential for recurrence. Patients were treated with about 50 - 100 mCi of radioiodine. In case of incomplete tumour resection, 150 - 200 mCi was administered</p> |

See Appendix D for full evidence tables.

### 1.1.7 Summary of the effectiveness evidence

**Table 3: Clinical evidence summary: Levothyroxine vs no additional suppression**

| Outcomes          | No of Participants (studies) Follow up | Quality of the evidence (GRADE)                                     | Relative effect (95% CI) | Anticipated absolute effects                        |  |
|-------------------|--|---|--------------------------|---|--|
|                   |  |   |                          | Risk with No additional suppression (mixed stratum) | Risk difference with TSH suppression (95% CI)  |
| Cancer Recurrence | 148 (1 study) 24-86 months             | ⊕⊕⊖⊖<br>VERY LOW <sup>1,2</sup><br>due to risk of bias, imprecision | RR 0.44 (0.18 to 1.09)   | 181 per 1000  | 101 fewer per 1000 (from 148 fewer to 16 more) |
| Mortality         | 148 (1 study) 24-86 months             | ⊕⊖⊖⊖<br>VERY LOW <sup>1,2</sup><br>due to risk of bias, imprecision | RR 0.32 (0.07 to 1.51)   | 83 per 1000   | 38 fewer per 1000 (from 52 fewer to 29 more)   |

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias  
2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

See Appendix F for full GRADE table

## 1.1.8 Economic evidence

### 1.1.8.1 Included studies

No health economic studies were included.

### 1.1.8.2 Excluded studies

No relevant health economic studies were excluded due to assessment of limited applicability or methodological limitations.

See also the health economic study selection flow chart in Appendix G.

## 1.1.9 Summary of included economic evidence

None.

### 1.1.10 Economic model

This area was not prioritised for new cost-effectiveness analysis.

### 1.1.11 Cost-consequence analysis

A cost-consequence analysis was conducted to compare the costs of offering TSH suppression or TSH adjustment therapy (where TSH is adjusted to normal value) to people who underwent surgery due to differentiated thyroid carcinoma, as described in the randomised trial included in the clinical review<sup>1</sup>. Achieving TSH suppression (mU/L= 0.1) requires a higher dosage of Levothyroxine (L-T4) compared to adjusting TSH to normal values (mU/L= 0.5 – 6.2). The dosages required to achieve the two states were estimated from the literature and are presented in table 4 for a person weighting 80kg. Cost per mg was calculated using British National Formulary (2020) and Prescription Cost Analysis 2020. The resulting cost per year indicates that people achieving TSH suppression has an incremental pharmaceutical cost per patient of £11.

**Table 4: Dosage and cost of L-T4 for TSH suppression and TSH adjustment**

| TSH aim                          | Dosage (80 kg)   | Cost per year | Source  |
|----------------------------------|------------------|---------------|---|
| TSH suppression (mU/L= 0.1)      | 204.8 µg per day | £62           | BNF 2020 <sup>27</sup><br>Prescription cost analysis 2020 <sup>22</sup> |
| TSH adjustment (mU/L= 0.5 – 6.2) | 168.8 µg per day | £51           | Burmeister 1992 <sup>14</sup>   |

The clinical review based on the included RCT<sup>1</sup> found that TSH suppression therapy compared to TSH adjustment therapy reduces, although not statistically significantly, the risk of dying and cancer recurrence (respectively, RR: 0.24, 0.03 to 2.07; RR:0.44, 0.18 to 1.09). See also Table 3 in section 1.1.6. Probabilities in the baseline arm (TSH adjustment) were converted into yearly probabilities and a cost-consequence analysis with a time horizon of 1 year was performed. Costs of FNAC See table 5 for the parameters used in the cost-consequence analysis.

**Table 5: Cost-consequence analysis**

| Parameter   | Value | Source                                     |
|---|-------|--|
| 1 year risk of recurrence without TSH suppression | 0.043 | Calculated from Abu-Touk 2015 <sup>1</sup> |

| Parameter                                     | Value  | Source   |
|---|--------|--|
| 1 year mortality risk without TSH suppression | 0.013  | Calculated from Abu-Touk 2015 <sup>1</sup>   |
| Risk ratio for recurrence                     | 0.44   | Abu-Touk 2015 <sup>1</sup>   |
| Risk ratio for mortality                      | 0.24   | Abu-Touk 2015 <sup>1</sup>   |
| Yearly cost                                   |        |  |
| TSH suppression therapy                       | £61.52 | BNF 2020 <sup>27</sup><br>Prescription cost analysis 2020 <sup>22</sup><br>Burmeister 1992 <sup>14</sup> |
| TSH adjustment therapy                        | £50.71 | BNF 2020 <sup>27</sup><br>Prescription cost analysis 2020 <sup>22</sup><br>Burmeister 1992 <sup>14</sup> |
| FNAC  | £299   | NHS Reference Costs 2019-2020{NHS England and NHS Improvement, 2020 #1938}                               |
| Thyroidectomy                                 | £4,791 | NHS Reference Costs 2019-2020{NHS England and NHS Improvement, 2020 #1938}                               |

The analysis found that in a cohort of 1000 patients, TSH suppression would prevent 24 recurrent cancers and 10 deaths during a time period of 12 months. Assuming that a recurrent cancer will require a FNAC assessment and a new thyroidectomy, each recurrence will cost to the NHS around £5,090 (this estimation does not include possible adjuvant treatments such as RAI).

The results of the cost-consequence analysis are presented in table 6.

**Table 6: Cost analysis results (per 1,000 people)**

| Strategy                              | N° of recurrence | N° of death | Cost (per patient) |
|---------------------------------------|------------------|-------------|--------------------|
| TSH suppression                       | 19               | 13          | £159               |
| TSH adjustment                        | 43               | 3           | £272               |
| Difference (Suppression – adjustment) | -24              | -10         | -£113              |

This analysis showed that TSH suppression therapy is potentially cost saving compared with TSH adjustment therapy. Although the cost of the levothyroxine required to achieve TSH suppression is higher due to the higher dosage needed, fewer recurrent cancers in the TSH suppressed group leads to important savings outweighing the additional pharmaceutical cost. On average, offering TSH suppression therapy instead of TSH adjustment therapy leads to savings for the NHS equal to £113 per patient.

This analysis should be interpreted with caution. The effectiveness is based on the single RCT included in the clinical review<sup>1</sup> which, although found improvement in mortality and recurrence, did not achieve statistical significance in neither of these outcomes. Moreover, the analysis is a cost analysis only and, as such, does not include any quality of life (QoL) aspect. People under TSH suppression therapy may have impaired QoL if compared with people with a normal level of TSH and are at higher risk of osteoporosis and cardiac complications, although the committee noted that with new suppression regimes people have no QoL impairment and very low risk of adverse events. Regardless of the quality of life of

people in the two arms, the very high effect on mortality found in Abo-Touk 2015<sup>1</sup> should ultimately lead to higher QALYs in the TSH-suppressed group.

In conclusion, this cost analysis found that TSH suppression therapy is cost saving compared to TSH adjustment therapy. The analysis should be interpreted with caution as the effectiveness is based on a single RCT with very high uncertainty.

### **1.1.12 Economic evidence statements**

No relevant economic evaluations were identified.

### **1.1.13 The committee's discussion and interpretation of the evidence**

#### **1.1.13.1 The outcomes that matter most**

The outcomes considered were mortality, quality of life, thyroglobulin levels, local cancer progression, incidence of distant metastases, cancer recurrence, incidence of osteoporosis, cardiac complications and incidence of second primary malignancy. All outcomes were regarded as critical and of equal weight for decision-making. Reasons for this critical status are explained as follows. Mortality was critical because this is the key harm to consider in cancer treatment, and quality of life was critical because it encompasses global effects that are patient-centred. Thyroglobulin levels were critical because they provide a direct and highly specific measure of recurrence. Local cancer progression, incidence of distant metastases, second primary malignancy and cancer recurrence were all critical because they provide a patient-centred clinically relevant measure of long term effectiveness. Finally, osteoporosis and cardiac complications were critical because these are known to be key potential harms from TSH suppression, and therefore essential for adequate weighing up of benefits and harms. The minimum follow-up time point required was three years and this study reported outcomes at 54 months.

#### **1.1.13.2 There was no evidence for quality of life, thyroglobulin levels, local cancer progression, incidence of distant metastases, osteoporosis, cardiac complications and second primary malignancy. The quality of the evidence**

For the 'TSH suppression versus no TSH suppression' review, only one paper was found. This was found to be at very serious risk of bias because of probable selection, performance and detection bias. Selection bias was likely due to a failure to report allocation concealment, performance bias was likely due to an inability to report blinding of patients and health care providers to the treatment being provided, and detection bias was probable due to no evidence that outcome assessors had been blinded to treatment allocation. Overall quality was further compromised by imprecision of estimates for both outcomes, leading to a final GRADE rating of very low.

#### **1.1.13.3 Benefits and harms**

The evidence involved a single study. The intention had been to stratify the analysis of data in this review to reveal patient groupings who might gain more (or less) clinical benefit from TSH suppression. There had been four stratification strategies, in terms of risk [very low risk/low risk /high risk /persistent disease], ethnicity [white/ Asian/Black/Other/Mixed], gender [male/female] and age [<55 years/>55 years]. In contrast to the usual method of stratification, where all permutations of all strategies would interact to form a multitude of possible substrata, it had been decided to run each stratification strategy independently, to avoid slicing the total number of papers into excessively small sub-groups. It had been hoped that such a stratification methodology might yield useful information on which categories of risk, ethnicity, gender or age group are independently associated with best results from TSH suppression. Thus, the aim of this review was not solely to evaluate the efficacy of TSH suppression but

also to evaluate the patient groupings for whom it would be most suitable. In this way, it was hoped it would effectively answer the question, 'who needs TSH suppression?'. Unfortunately, the existence of only one study meant that it was not possible to put this stratification methodology to use.

The evidence suggested a benefit for TSH suppression over no TSH suppression in terms of reduced cancer recurrence and reduced mortality which the committee considered to be clinically important benefits. However, this evidence was from a single small study and the evidence was graded as very low quality partly due to uncertainty in the effect estimates, and there was no accompanying evidence assessing potential harms or risks associated with TSH suppression such as osteoporosis or cardiac complications. Although the sample in this study were mostly female, the risk levels and the age categories were mixed, and ethnicity was unreported, so it was not possible to associate the results with any particular risk, age or ethnicity stratum. Because the evidence base was weak, and lacked information on harms, the committee decided to form recommendations largely through consensus. This consensus opinion reflects current clinical practice and also mirrors the low quality evidence.

### **Who to offer TSH suppression**

It was agreed that patients with very low risk thyroid cancers such as microcarcinomas, or those who do not need RAI, should not be offered TSH suppression. Low risk thyroid cancers were defined by the committee as follows. A low risk thyroid cancer would have no evidence of clinical lymph node metastases, no evidence of aggressive histology, no evidence of vascular invasion, no evidence of incomplete macroscopic tumour resection, and no evidence of distant metastases. The tumour would be intrathyroid with absent macroscopic extra-thyroid extension. In patients treated with radioiodine, there would be no uptake outside the thyroid bed on post-therapeutic whole-body scan. In the case of a low risk follicular thyroid cancer, the tumour would be well-differentiated with capsular invasion only or less than four foci of vascular invasion. A solitary papillary microcarcinoma would be considered very low risk. For such patients with such low risk cancers the risks of recurrence or mortality are believed to be so low that TSH suppression would benefit only a very small number of people. Given that the adverse effects of TSH suppression on bone and cardiac health would affect a far greater proportion of people, the balance of benefits and harms was agreed to strongly indicate avoidance of TSH suppression in this group.

In contrast, the committee agreed that the situation would be different for those patients who had been given total thyroidectomy and RAI, as these treatments are only provided when the perceived risks of recurrence, spread or mortality are higher. For such patients the balance of benefits and harms would shift towards an overall benefit for TSH suppression, as although the risks of recurrence, spread and mortality without TSH suppression might still be lower than the adverse effects experienced with TSH suppression, the overall impact of thyroid cancer progression would still exceed the impact of the treatment complications. Therefore, for such patients, TSH suppression may be offered to maintain TSH levels below 0.1mIU/L.

### **Assessing and managing response to TSH suppression**

After initiating this treatment, the patient's response to the suppression should be monitored. The committee agreed that this should be done by dynamic risk stratification between 9 and at 12 months after initial treatment to consider reducing the levels of TSH suppression. If the person has an excellent response to treatment, suppression could be reduced to achieve a TSH level of between 0.3 and 2.0 IU/L. This is on the basis that initial treatments and TSH suppression had probably eliminated the cancer and that further high levels of suppression would possibly cause more harm than good. If, on the other hand, the response were poor, with persistent biochemical or structural disease, then the high levels of suppression (<0.1 mIU/L) should be continued, on the basis that the benefits of continued treatment would outweigh the possible harms. For an intermediate level of response at 1 year, a compromise approach should be taken, with an intermediate level of suppression adopted (0.1-0.5

mIU/L), on the basis that a lower level of suppression might lead to a net increase in harm arising from the condition, whilst a higher level of suppression might lead to a net increase in harm arising from TSH suppression. Furthermore, based on clinical experience, the committee agreed that all patient's comorbidities need to be taken into consideration when planning TSH suppression. Significant comorbidities, particularly those of a cardiac nature, may mean that total suppression or a low normal level of TSH should be avoided. In this way, TSH suppression treatment should be stratified according to response to the treatment and comorbidities.

The committee therefore used consensus to make different recommendations about TSH suppression across different risk strata. The conclusion was that TSH suppression was definitely indicated for those at higher risk and could be avoided for those at lowest risk. However, the committee did not make any consensus recommendations based on age, gender or ethnicity. This was because the committee did not feel that there were any compelling reasons, in the absence of any evidence, to suggest that the balance of benefits and harms of TSH suppression should vary across age, gender or ethnic groups.

#### **1.1.13.4 Cost effectiveness and resource use**

No health economic evidence was found for this question.

The one trial included in the clinical review, although at serious risk of bias, showed that offering levothyroxine at a TSH suppression dosage can potentially reduce cancer recurrence and mortality. As TSH suppression requires a higher dosage of levothyroxine compared to no TSH suppression therapy, the cost of the intervention is uncertain.

A cost comparison analysis was undertaken and presented to the committee comparing the cost and potential outcomes of TSH suppression vs no TSH suppression using UK sources for unit cost and the trial included in the clinical review for treatment effectiveness. The analysis showed that the higher levothyroxine required for achieving TSH suppression would increase the cost of thyroxine by £11 a year. However, savings due to preventing cancer recurrences are expected to highly outweigh the small additional costs leading to a saving estimated to be £113 per patient per year. This analysis was based on a single RCT with a serious risk of bias and imprecision, as it failed to reach statistical significance in either of the study's outcomes. Moreover, it does not account for potential adverse events of TSH suppression therapy. The committee noted that TSH suppression therapy does not reduce people quality of life although it can increase the risk of osteoporosis or cardiac complications.

The committee decided to recommend TSH suppression therapy to people who underwent total thyroidectomy and RAI. This reflects current practice in England and it is supported by the very low quality evidence provided, which found TSH suppression to be potentially cost saving and to reduce recurrence and mortality. The committee recommended to reduce TSH suppression to people with excellent improvement as assessed by Dynamic Risk Stratification (DRS), which allows to predict risk of recurrence. This recommendation should reduce the number of people with low risk of recurrence under a strict TSH suppression therapy, thus saving cost for the NHS and reducing the risk of TSH suppression adverse events like osteoporosis and cardiac complications.

#### **1.1.13.5 Other factors the committee took into account**

**Dynamic risk stratification** is an established system used to assess the risk of recurrence of thyroid cancer by evaluating the patient's response to treatment. This re-evaluation of risk allows the follow-up strategy to be modified according to treatment response. The response to treatment is based on measurement of serum thyroglobulin Tg (and anti-thyroglobulin antibody TgAb) and on ultrasound imaging. An excellent response (undetectable Tg, undetectable TgAb, negative imaging) in a patient initially classified as low risk has a very

low risk of recurrence. If the ultrasound shows persistent foci of tumour, the response is classified as structurally incomplete. A response termed indeterminate is when the Tg is measurable but low whilst a biochemically incomplete response consists of an elevated Tg.

#### **1.1.14 Recommendations supported by this evidence review**

This evidence review supports recommendations 1.4.1 to 1.4.5.

# References

1. Abo-Touk NA, Zayed DH. The efficacy of thyrotropin suppression therapy in treatment of differentiated thyroid cancer after total thyroidectomy. *Forum of clinical oncology*. 2015; 6(2):24-33
2. Ahmed CKEAFBFZNBSS. Lean body mass-based levothyroxine replacement in young athyrotic patients with differentiated carcinoma of thyroid. *Indian Journal of Endocrinology and Metabolism*. 2013; 17(2):254-259
3. Akirov A, Fazelzad R, Ezzat S, Thabane L, Sawka AM. A Systematic Review and Meta-Analysis of Patient Preferences for Combination Thyroid Hormone Treatment for Hypothyroidism. *Frontiers in Endocrinology*. 2019; 10:477
4. Almodovar Ruiz F, Maldonado Castro G, De Luis D, Lahera M, Varela da Costa C. Suppressive therapy with levothyroxine for solitary thyroid nodules. *Anales de Medicina Interna*. 2000; 17(2):99-101
5. Appelhof BC, Fliers E, Wekking EM, Schene AH, Huyser J, Tijssen JG et al. Combined therapy with levothyroxine and liothyronine in two ratios, compared with levothyroxine monotherapy in primary hypothyroidism: a double-blind, randomized, controlled clinical trial. *Journal of Clinical Endocrinology and Metabolism*. 2005; 90(5):2666-2674
6. Boguszewski CL, Pedrazzani M, Graf H. Assessment of levothyroxine suppressive therapy in patients with solitary thyroid nodules: a double-blind, placebo-controlled, clinical trial. *Arquivos Brasileiros de Endocrinologia e Metabologia*. 1998; 42(3):214-221
7. Brancatella A, Marcocci C. TSH suppressive therapy and bone. *Endocrine Connections*. 2020; 9(7):R158-R172
8. Brun VH, Eriksen AH, Selseth RI, Johansson K, Vik R, Davidsen B et al. Patient tailored levothyroxine dosage with pharmacokinetic/pharmacodynamic modeling: a novel approach after total thyroidectomy. *Thyroid*. 2021; 12:12
9. Bunevicius R, Jakuboniene N, Jakubonien N, Jurkevicius R, Cernicat J, Lasas L et al. Thyroxine vs thyroxine plus triiodothyronine in treatment of hypothyroidism after thyroidectomy for Graves' disease. *Endocrine*. 2002; 18(2):129-133
10. Bunevicius R, Prange AJ. Selective hormone replacement in hypothyroidism: maintenance mood. *Sixth world congress of biological psychiatry, nice, france June 22-27, 1997*. 1997;
11. Bunevicius R, Prange AJ. Triiodothyronine improves mental state of hypothyroid patients compensated with thyroxine alone. *Xxist collegium internationale neuro-psychofarmacologicum, glasgow, scotland 12th-16th july, 1998*. 1998;
12. Bunevicius R, Prange Jr AJ. Mental improvement after replacement therapy with thyroxine plus triiodothyronine: relationship to cause of hypothyroidism. *International Journal of Neuropsychopharmacology*. 2000; 3(2):167-174
13. Burgos N, Toloza FJ, Singh Ospina NM, Brito JP, Salloum RG, Hassett LC et al. Clinical Outcomes After Discontinuation of Thyroid Hormone Replacement - A Systematic Review and Meta-Analysis. *Thyroid : official journal of the American Thyroid Association*. 2020; 31(5):740-751

14. Burmeister LA, Goumaz MO, Mariash CN, Oppenheimer JH. Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer. *Journal of Clinical Endocrinology and Metabolism*. 1992; 75(2):344-350
15. Celi FS, Zemskova M, Linderman JD, Babar NI, Skarulis MC, Csako G et al. The pharmacodynamic equivalence of levothyroxine and liothyronine: a randomized, double blind, cross-over study in thyroidectomized patients. *Clinical Endocrinology*. 2010; 72(5):709-715
16. Clyde PW, Harari AE, Getka EJ, Shakir KMM. Combined Levothyroxine Plus Liothyronine Compared with Levothyroxine Alone in Primary Hypothyroidism: A Randomized Controlled Trial. *Journal of the American Medical Association*. 2003; 290(22):2952-2958
17. Eustatia-Rutten CF, Corssmit EP, Pereira AM, Frölich M, Bax JJ, Romijn JA et al. Quality of life in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomized controlled trial. *Clinical Endocrinology*. 2006; 64(3):284-291
18. Faber J, Galloe AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. *European Journal of Endocrinology*. 1994; 130(4):350-356
19. Fischman A, Domínguez JM. Combined therapy with levothyroxine and liothyronine for hypothyroidism. *Medwave*. 2018; 18(8):e7376
20. Fussey JM, Khan H, Ahsan F, Prashant R, Pettit L. Thyroid-stimulating hormone suppression therapy for differentiated thyroid cancer: The role for a combined T3/T4 approach. *Head and Neck*. 2017; 39(12):2567-2572
21. Greenspan SL, Greenspan FS. The effect of thyroid hormone on skeletal integrity. *Annals of Internal Medicine*. 1999; 130(9):750-758
22. Health and Social Care Information Centre. Prescription cost analysis, England [updated December 2021]. Available from: <https://www.nhsbsa.nhs.uk/prescription-data/dispensing-data/prescription-cost-analysis-pca-data> Last accessed:
23. Helfand M, Crapo LM. Monitoring therapy in patients taking levothyroxine. *Annals of Internal Medicine*. 1990; 113(6):450-454
24. Hennessey JV, Espaillet R. Current evidence for the treatment of hypothyroidism with levothyroxine/levotriiodothyronine combination therapy versus levothyroxine monotherapy. *International Journal of Clinical Practice*. 2018; 72(2):1-14
25. Iakovou I, Chrisoulidou A, Balaris V, Balaris C, Doumas A, Karatzas N. Acute effects of recombinant human TSH on bone markers in differentiated thyroid cancer. *Hellenic Journal of Nuclear Medicine*. 2010; 13(3):208-212
26. Influence of Surgery + 131I treatment + TSH Inhibition Therapy on Curative Effect and Survival Time of Patients with Stage IV Differentiated Thyroid Carcinoma. *Anti-tumor pharmacy*. 2018; 8(4):596-599 and 603
27. Joint Formulary Committee. *British National Formulary (BNF)*. 67th ed. London. British Medical Association and The Royal Pharmaceutical Society of Great Britain,. 2014. Available from: <http://www.bnf.org.uk>
28. Lee EK, Kang YE, Park YJ, Koo BS, Chung KW, Ku EJ et al. A Multicenter, Randomized, Controlled Trial for Assessing the Usefulness of Suppressing Thyroid Stimulating Hormone Target Levels after Thyroid Lobectomy in Low to Intermediate

- Risk Thyroid Cancer Patients (MASTER): A Study Protocol. *Endocrinology and Metabolism*. 2021; 26:26
29. Lee JC, Song BS, Kang YM, Kim YR, Kang YE, Lee JH et al. Effect of Thyroid-Stimulating Hormone Suppression on Muscle Function After Total Thyroidectomy in Patients With Thyroid Cancer. *Frontiers in Endocrinology*. 2021; 12 (no pagination)(769074)
  30. Lee Y, Yoon BH, Lee S, Chung YK, Lee YK. Risk of Osteoporotic Fractures after Thyroid-stimulating Hormone Suppression Therapy in Patients with Thyroid Cancer. *Journal of Bone Metabolism*. 2019; 26(1):45-50
  31. Ma C, Xie J, Huang X, Wang G, Wang Y, Wang X et al. Thyroxine alone or thyroxine plus triiodothyronine replacement therapy for hypothyroidism. *Nuclear Medicine Communications*. 2009; 30(8):586-593
  32. Mendonca Monteiro de Barros G, Madeira M, Vieira Neto L, de Paula Paranhos Neto F, Carvalho Mendonca LM, Correa Barbosa Lima I et al. Bone mineral density and bone microarchitecture after long-term suppressive levothyroxine treatment of differentiated thyroid carcinoma in young adult patients. *Journal of Bone and Mineral Metabolism*. 2016; 34(4):417-421
  33. Quan ML, Pasiaka JL, Rorstad O. Bone mineral density in well-differentiated thyroid cancer patients treated with suppressive thyroxine: a systematic overview of the literature. *Journal of Surgical Oncology*. 2002; 79(1):62-69; discussion 69-70
  34. Regalbuto C, Maiorana R, Alagona C, Paola RD, Cianci M, Alagona G et al. Effects of either LT4 monotherapy or LT4/LT3 combined therapy in patients totally thyroidectomized for thyroid cancer. *Thyroid*. 2007; 17(4):323-331
  35. Saravanan P, Simmons DJ, Greenwood R, Peters TJ, Dayan CM. Partial substitution of thyroxine (T4) with tri-iodothyronine in patients on T4 replacement therapy: results of a large community-based randomized controlled trial. *Journal of Clinical Endocrinology and Metabolism*. 2005; 90(2):805-812
  36. Schaffler A. Hormone replacement after thyroid and parathyroid surgery. *Deutsches Arzteblatt International*. 2010; 107(47):827-834
  37. Sugitani I, Fujimoto Y. Does postoperative thyrotropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma? A randomized controlled trial. *Journal of Clinical Endocrinology and Metabolism*. 2010; 95(10):4576-4583
  38. Sugitani I, Fujimoto Y. Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study. *Surgery*. 2011; 150(6):1250-1257
  39. Valle LA, Gorodeski Baskin RL, Porter K, Sipos JA, Khawaja R, Ringel MD et al. In thyroidectomized patients with thyroid cancer, a serum thyrotropin of 30  $\mu$ U/mL after thyroxine withdrawal is not always adequate for detecting an elevated stimulated serum thyroglobulin. *Thyroid*. 2013; 23(2):185-193
  40. van Vliet NA, Noordam R, van Klinken JB, Westendorp RG, Bassett JD, Williams GR et al. Thyroid Stimulating Hormone and Bone Mineral Density: Evidence From a Two-Sample Mendelian Randomization Study and a Candidate Gene Association Study. *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*. 2018; 33(7):1318-1325
  41. Vera L, Gay S, Campomenosi C, Paolino S, Pera G, Monti E et al. Ten-year estimated risk of bone fracture in women with differentiated thyroid cancer under TSH-suppressive levothyroxine therapy. *Endokrynologia Polska*. 2016; 67(4):350-358

42. Vestergaard P, Rejnmark L, Mosekilde L. Influence of hyper- and hypothyroidism, and the effects of treatment with antithyroid drugs and levothyroxine on fracture risk. *Calcified Tissue International*. 2005; 77(3):139-144
43. Wang MY, Han ZQ, Gong XW, Li Q, Ma J. TSH-suppressive therapy can reduce bone mineral density in patients with differentiated thyroid carcinoma: a meta-analysis. *European Review for Medical and Pharmacological Sciences*. 2020; 24(2):922-929
44. Yamazaki CA, Padovani RP, Biscolla RP, Ikejiri ES, Marchetti RR, Castiglioni ML et al. Lithium as an adjuvant in the postoperative ablation of remnant tissue in low-risk thyroid carcinoma. *Thyroid*. 2012; 22(10):1002-1006
45. Yoon BH, Lee Y, Oh HJ, Kim SH, Lee YK. Influence of Thyroid-stimulating Hormone Suppression Therapy on Bone Mineral Density in Patients with Differentiated Thyroid Cancer: A Meta-analysis. *Journal of Bone Metabolism*. 2019; 26(1):51-60

# Appendices

## Appendix A – Review protocols

### A.1 Review protocol for TSH suppression vs no TSH suppression

| Field                        | Content  |
|------------------------------|--|
| PROSPERO registration number | Not registered   |
| Review title                 | Clinical and cost effectiveness of thyroid stimulating hormone (TSH) suppression versus no TSH suppression in different groups of people after thyroidectomy and radioactive iodine (RAI). The different population strata will be characterised by recurrence risk, ethnicity, gender and age |
| Review question              | What is the clinical and cost effectiveness of TSH suppression versus no TSH suppression in different population groups, characterised by recurrence risk, ethnicity, gender and age?  |
| Objective                    | To determine the patient groups who are most suitable for TSH suppression  |
| Searches                     | The following databases (from inception) will be searched: <ul style="list-style-type: none"><li>• Cochrane Central Register of Controlled Trials (CENTRAL)</li><li>• Cochrane Database of Systematic Reviews (CDSR)</li></ul>   |

|                                   |  |
|-----------------------------------|--|
|                                   | <ul style="list-style-type: none"> <li>• Embase</li> <li>• MEDLINE</li> </ul> <p>Searches will be restricted by:</p> <ul style="list-style-type: none"> <li>• English language</li> <li>• Human studies</li> <li>• Letters and comments are excluded.</li> </ul> <p>Other searches:</p> <ul style="list-style-type: none"> <li>• Inclusion lists of relevant systematic reviews will be checked by the reviewer.</li> </ul> <p>The searches may be re-run 6 weeks before final committee meeting and further studies retrieved for inclusion if relevant.</p> <p>The full search strategies will be published in the final review.</p> <p>Medline search strategy to be quality assured using the PRESS evidence-based checklist (see methods chapter for full details).</p> |
| Condition or domain being studied | Thyroid cancer   |
| Population                        | <p>Inclusion:</p> <p>People aged 16 or over who have had thyroidectomy and RAI for differentiated thyroid cancer. People</p>   |

|   |  |
|---|--|
|   | <p>will need to have had total or near total thyroidectomy.</p> <p>Exclusion:</p> <p>Children under 16</p>   |
| Intervention/Exposure/Test                        | TSH suppression (using high doses of levothyroxine [T4] or other TSH-lowering agents, such as 'armour thyroid' [T4 + liothyronine] or liothyronine alone)  |
| Comparator/Reference standard/Confounding factors | <p>No TSH suppression.</p> <p>(Note that patients, in the absence of functioning thyroid tissue, will still receive levothyroxine doses sufficient to prevent hypothyroidism, although unless actual TSH suppression is indicated the doses will not be sufficient to reduce TSH levels below normal levels)</p>   |
| Types of study to be included                     | <p>Published NMAs and IPDs will be considered for inclusion.</p> <ul style="list-style-type: none"> <li>• Systematic reviews</li> <li>• RCTs</li> </ul> <p>Non-randomised studies (any controlled studies such as prospective or retrospective cohorts, or case control studies, with appropriate adjustment for plausible confounders) will be excluded</p> |
| Other exclusion criteria                          | <p>Non-English language studies.</p> <p>Conference abstracts will be excluded as it is expected there will be sufficient full text published studies</p>   |

|   |  |
|---|--|
|   | available.   |
| Context                                 | TSH suppression is now an established intervention for this review population, but there is concern that it may not always be given to the people who will benefit the most and may also sometimes be given to people who may not benefit and may even be harmed. Therefore there is a need for a systematic review to allow an evidence-based recommendation in this area.  |
| Primary outcomes (critical outcomes)    | <p>All outcomes are considered equally important for decision making and therefore have all been rated as critical:</p> <ul style="list-style-type: none"> <li>• mortality</li> <li>• quality of life (any validated tools)</li> <li>• thyroglobulin levels</li> <li>• local cancer progression</li> <li>• incidence of distant metastases</li> <li>• cancer recurrence</li> <li>• osteoporosis</li> <li>• cardiac complications (reported or composite outcomes allowed)</li> <li>• second primary malignancy</li> </ul> <p>Time of follow up: longest available but minimum of 3 years</p> |
| Secondary outcomes (important outcomes) | None   |

|   |  |
|---|--|
| <p>Data extraction (selection and coding)</p> | <p>EndNote will be used for reference management, sifting, citations and bibliographies. All references identified by the searches and from other sources will be screened for inclusion. 10% of the abstracts will be reviewed by two reviewers, with any disagreements resolved by discussion or, if necessary, a third independent reviewer. The full text of potentially eligible studies will be retrieved and will be assessed in line with the criteria outlined above.</p> <p>A standardised form will be used to extract data from studies (see <a href="#">Developing NICE guidelines: the manual</a> section 6.4).</p> <p>10% of all evidence reviews are quality assured by a senior research fellow. This includes checking:</p> <ul style="list-style-type: none"> <li>• papers were included /excluded appropriately</li> <li>• a sample of the data extractions</li> <li>• correct methods are used to synthesise data</li> <li>• a sample of the risk of bias assessments</li> </ul> <p>Disagreements between the review authors over the risk of bias in particular studies will be resolved by discussion, with involvement of a third review author where necessary.</p> |
| <p>Risk of bias (quality) assessment</p>      | <p>Risk of bias will be assessed using the appropriate checklist as described in Developing NICE guidelines: the manual.</p> <p>For Intervention reviews the following checklist will be used according to study design being assessed:</p> <ul style="list-style-type: none"> <li>• Systematic reviews: Risk of Bias in Systematic Reviews (ROBIS)</li> <li>• Randomised Controlled Trial: Cochrane RoB (2.0)</li> <li>• Non randomised study, including cohort studies: Cochrane ROBINS-I (if a lack of any RCTs necessitate dropping down to non-randomised studies)</li> </ul>   |

|                                    |   |
|------------------------------------|---|
| <p>Strategy for data synthesis</p> | <p>Where possible, data will be meta-analysed. Pairwise meta-analyses will be performed using Cochrane Review Manager (RevMan5) to combine the data given in all studies for each of the outcomes stated above. A fixed effect meta-analysis, with weighted mean differences for continuous outcomes and risk ratios for binary outcomes will be used, and 95% confidence intervals will be calculated for each outcome.</p> <p>Heterogeneity between the studies in effect measures will be assessed using the <math>I^2</math> statistic and visually inspected. We will consider an <math>I^2</math> value greater than 50% indicative of substantial heterogeneity. Sensitivity analyses will be conducted based on pre-specified subgroups using stratified meta-analysis to explore the heterogeneity in effect estimates. If this does not explain the heterogeneity, the results will be presented using random-effects.</p> <p>GRADE pro will be used to assess the quality of each outcome, taking into account individual study quality and the meta-analysis results. The 4 main quality elements (risk of bias, indirectness, inconsistency and imprecision) will be appraised for each outcome.</p> <p>Publication bias is tested for when there are more than 5 studies for an outcome.</p> <p>Other bias will only be taken into consideration in the quality assessment if it is apparent.</p> <p>Where meta-analysis is not possible, data will be presented and quality assessed individually per outcome.</p> <p>If sufficient data is available to make a network of treatments, WinBUGS will be used for network meta-analysis.</p> |
|------------------------------------|---|

|                           |   |
|---------------------------|---|
| Analysis of sub-groups    | <p><u>Stratification (up-front stratification of analysis, NOT conditional on heterogeneity of prior meta-analysis)</u></p> <ul style="list-style-type: none"> <li>• very low risk/ low risk /high risk /persistent disease</li> <li>• Ethnicity (white/white other, Asian, Black, Other/Mixed)</li> <li>• Gender</li> <li>• Age (&lt;55, ≥55)</li> </ul> <p>The above strata will also have an unknown/mixed category (mixed where one category makes up &lt;75% of total)</p> <p><u>Sub-grouping (conditional stratification if heterogeneity seen in initial unstratified meta-analysis)</u></p> <p>If serious or very serious heterogeneity (I<sup>2</sup>&gt;50%) is present within any stratum, sub-grouping will occur according to the following strategy:</p> <ul style="list-style-type: none"> <li>• Duration of TSH supplementation (&lt;5, 5-10 and &gt;10 yrs)</li> <li>• Level of TSH suppression (low normal vs very low vs extremely low)</li> </ul> |
| Type and method of review | <ul style="list-style-type: none"> <li><input checked="" type="checkbox"/> Intervention</li> <li><input type="checkbox"/> Diagnostic</li> <li><input type="checkbox"/> Prognostic</li> <li><input type="checkbox"/> Qualitative</li> <li><input type="checkbox"/> Epidemiologic</li> <li><input type="checkbox"/> Service Delivery</li> </ul>   |

|                         |   |
|-------------------------|---|
|                         | <input type="checkbox"/> Other (please specify)   |
| Language                | English   |
| Country                 | England   |
| Named contact           | <p><b>Named contact</b><br/>National Guideline Centre</p> <p><b>Organisational affiliation of the review</b><br/>National Institute for Health and Care Excellence (NICE) and the National Guideline Centre</p>   |
| Review team members     | <p>From the National Guideline Centre:</p> <p>Carlos Sharpin, Guideline lead</p> <p>Mark Perry, Senior systematic reviewer</p> <p>Alfredo Mariani, Health economist</p> <p>Lina Gulhane, Head of Information specialists</p>  |
| Funding sources/sponsor | This systematic review is being completed by the National Guideline Centre which receives funding from NICE.  |
| Conflicts of interest   | All guideline committee members and anyone who has direct input into NICE guidelines (including the evidence review team and expert witnesses) must declare any potential conflicts of interest in line with NICE's code of practice for declaring and dealing with conflicts of interest. Any relevant interests, or changes to interests, will also be declared publicly at the start of each guideline committee meeting. Before each meeting, any potential conflicts of interest will be considered by the guideline committee |

|  |   |
|--|---|
|  | Chair and a senior member of the development team. Any decisions to exclude a person from all or part of a meeting will be documented. Any changes to a member's declaration of interests will be recorded in the minutes of the meeting. Declarations of interests will be published with the final guideline.   |
| Collaborators  | Development of this systematic review will be overseen by an advisory committee who will use the review to inform the development of evidence-based recommendations in line with section 3 of <a href="https://www.nice.org.uk/guidance/indevelopment/gid-ng10150/documents">Developing NICE guidelines: the manual</a> . Members of the guideline committee are available on the NICE website: <a href="https://www.nice.org.uk/guidance/indevelopment/gid-ng10150/documents">https://www.nice.org.uk/guidance/indevelopment/gid-ng10150/documents</a> |
| Other registration details                               | N/A   |
| Reference/URL for published protocol                     | N/A   |
| Dissemination plans                                      | <p>NICE may use a range of different methods to raise awareness of the guideline. These include standard approaches such as:</p> <ul style="list-style-type: none"> <li>• notifying registered stakeholders of publication</li> <li>• publicising the guideline through NICE's newsletter and alerts</li> <li>• issuing a press release or briefing as appropriate, posting news articles on the NICE website, using social media channels, and publicising the guideline within NICE.</li> </ul>   |
| Keywords   | None  |
| Details of existing review of same topic by same authors | N/A   |

|                              |  |
|------------------------------|--|
| Additional information       | N/A  |
| Details of final publication | <a href="http://www.nice.org.uk">www.nice.org.uk</a> |

## A.2 Review protocol health economic evidence

|                        |  |
|------------------------|--|
| <b>Review question</b> | <b>All questions – health economic evidence</b>  |
| <b>Objectives</b>      | To identify health economic studies relevant to any of the review questions.   |
| <b>Search criteria</b> | <ul style="list-style-type: none"> <li>• Populations, interventions and comparators must be as specified in the clinical review protocol above.</li> <li>• Studies must be of a relevant health economic study design (cost–utility analysis, cost-effectiveness analysis, cost–benefit analysis, cost–consequences analysis, comparative cost analysis).</li> <li>• Studies must not be a letter, editorial or commentary, or a review of health economic evaluations. (Recent reviews will be ordered although not reviewed. The bibliographies will be checked for relevant studies, which will then be ordered.)</li> <li>• Unpublished reports will not be considered unless submitted as part of a call for evidence.</li> <li>• Studies must be in English.</li> </ul>  |
| <b>Search strategy</b> | A health economic study search will be undertaken using population-specific terms and a health economic study filter – see Appendix B below.   |
| <b>Review strategy</b> | <p>Studies not meeting any of the search criteria above will be excluded. Studies published before 2005, abstract-only studies and studies from non-OECD countries or the USA will also be excluded.</p> <p>Each remaining study will be assessed for applicability and methodological limitations using the NICE economic evaluation checklist which can be found in appendix H of Developing NICE guidelines: the manual (2014).{National Institute for Health and Care Excellence, 2014 #23}</p> <p><b>Inclusion and exclusion criteria</b></p> <ul style="list-style-type: none"> <li>• If a study is rated as both ‘Directly applicable’ and with ‘Minor limitations’, then it will be included in the guideline. A health economic evidence table will be completed, and it will be included in the health economic evidence profile.</li> <li>• If a study is rated as either ‘Not applicable’ or with ‘Very serious limitations’, then it will usually be excluded from the guideline. If it is excluded, then a health economic evidence table will not be completed, and it will not be included in the health economic evidence profile.</li> <li>• If a study is rated as ‘Partially applicable’, with ‘Potentially serious limitations’ or both then there is discretion over whether it should be included.</li> </ul> |

## **Where there is discretion**

The health economist will make a decision based on the relative applicability and quality of the available evidence for that question, in discussion with the guideline committee if required. The ultimate aim is to include health economic studies that are helpful for decision-making in the context of the guideline and the current NHS setting. If several studies are considered of sufficiently high applicability and methodological quality that they could all be included, then the health economist, in discussion with the committee if required, may decide to include only the most applicable studies and to selectively exclude the remaining studies. All studies excluded on the basis of applicability or methodological limitations will be listed with explanation in the excluded health economic studies appendix below.

The health economist will be guided by the following hierarchies.

### *Setting:*

- UK NHS (most applicable).
- OECD countries with predominantly public health insurance systems (for example, France, Germany, Sweden).
- OECD countries with predominantly private health insurance systems (for example, Switzerland).
- Studies set in non-OECD countries or in the USA will be excluded before being assessed for applicability and methodological limitations.

### *Health economic study type:*

- Cost–utility analysis (most applicable).
- Other type of full economic evaluation (cost–benefit analysis, cost–effectiveness analysis, cost–consequences analysis).
- Comparative cost analysis.
- Non-comparative cost analyses including cost-of-illness studies will be excluded before being assessed for applicability and methodological limitations.

### *Year of analysis:*

- The more recent the study, the more applicable it will be.
- Studies published in 2005 or later but that depend on unit costs and resource data entirely or predominantly from before 2005 will be rated as 'Not applicable'.
- Studies published before 2005 will be excluded before being assessed for applicability and methodological limitations.

### *Quality and relevance of effectiveness data used in the health economic analysis:*

- The more closely the clinical effectiveness data used in the health economic analysis match with the outcomes of the studies included in the clinical

review the more useful the analysis will be for decision-making in the guideline.

## Appendix B – Literature search strategies

The literature searches for these reviews are detailed below and complied with the methodology outlined in Developing NICE guidelines: the manual, 2014 (updated 2020) <https://www.nice.org.uk/process/pmg20/chapter/identifying-the-evidence-literature-searching-and-evidence-submission>.

For more information, please see the Methodology review published as part of the accompanying documents for this guideline.

### Clinical literature search strategy

This literature search strategy was used for the following review:

- What is the clinical and cost effectiveness of TSH suppression versus no TSH suppression in different population groups, characterised by recurrence risk, ethnicity, gender and age?

Searches were constructed using a PICO framework where population (P) terms were combined with Intervention (I) and in some cases Comparison (C) terms. Outcomes (O) are rarely used in search strategies for interventions as these concepts may not be well described in title, abstract or indexes and therefore difficult to retrieve. Search filters were applied to the search where appropriate.

**Table 7: Database parameters, filters and limits applied**

| Database                     | Dates searched                             | Search filters and limits applied  |
|------------------------------|--|--|
| Medline (OVID)               | 1946 – 13 January 2022                     | Randomised controlled trials<br>Systematic review studies<br>Observational studies<br><br>Exclusions (animal studies, letters, comments, editorials, case studies/reports, children)<br><br>English language                       |
| Embase (OVID)                | 1974 – 13 January 2022                     | Randomised controlled trials<br>Systematic review studies<br>Observational studies<br><br>Exclusions (animal studies, letters, comments, editorials, case studies/reports, conference abstracts, children)<br><br>English language |
| The Cochrane Library (Wiley) | Cochrane Database of Systematic Reviews to | Exclusions (clinical trials, conference abstracts)   |

| Database  | Dates searched   | Search filters and limits applied  |
|---|--|--|
|   | Issue 12 of 12, December 2021<br>Cochrane Central Register of Controlled Trials to Issue 12 of 12, December 2021 |  |
| Epistemonikos<br>(The Epistemonikos Foundation) | Inception – 13 January 2022  | Systematic review<br><br>Exclusions (Cochrane reviews)<br><br>English language |

### Medline (Ovid) search terms

|     |   |
|-----|---|
| 1.  | exp Thyroid Neoplasms/  |
| 2.  | (thyroid adj3 (cancer* or carcinom* or microcarcinoma* or tumo?r* or neoplasm* or metast* or adenoma* or adenocarcinom* or node* or nodul* or nodal or lump* or papillar* or swollen or swell* or anaplastic or sarcoma* or cyst* or malignan*)).ti,ab. |
| 3.  | DTC.ti,ab.  |
| 4.  | ((papillar* or anaplastic) adj2 (cancer* or carcinom* or tumo?r* or neoplasm* or metast* or adenoma* or adenocarcinom* or nodul* or node* or lump*)).ti,ab.   |
| 5.  | or/1-4  |
| 6.  | letter/   |
| 7.  | editorial/  |
| 8.  | news/   |
| 9.  | exp historical article/   |
| 10. | Anecdotes as Topic/   |
| 11. | comment/  |
| 12. | case report/  |
| 13. | (letter or comment*).ti.  |
| 14. | or/6-13   |
| 15. | randomized controlled trial/ or random*.ti,ab.  |
| 16. | 14 not 15   |
| 17. | animals/ not humans/  |
| 18. | exp Animals, Laboratory/  |
| 19. | exp Animal Experimentation/   |
| 20. | exp Models, Animal/   |
| 21. | exp Rodentia/   |
| 22. | (rat or rats or mouse or mice or rodent*).ti.   |
| 23. | or/16-22  |
| 24. | 5 not 23  |
| 25. | limit 24 to english language  |
| 26. | (exp child/ or exp pediatrics/ or exp infant/) not (exp adolescent/ or exp adult/ or exp middle age/ or exp aged/)  |
| 27. | 25 not 26   |
| 28. | exp Thyrotropin/  |
| 29. | (thyrotropin* or thyreotropin* or thyrotrophin* or thyrotropic).ti,ab.  |
| 30. | (thyroid stimulating adj2 hormone*).ti,ab.  |
| 31. | TSH.ti,ab.  |
| 32. | ((thyroid or hormon*) adj4 (suppress* or lower*)).ti,ab.  |

|     |  |
|-----|--|
| 33. | Thyroxine/   |
| 34. | (thyroxine or thyroxin or tetraiodothyronine or levothyroxine or Lthyroxine or T4 or LT4).ti,ab.   |
| 35. | Eltroxin.ti,ab.  |
| 36. | Triiodothyronine/  |
| 37. | (triiodothyronine or tri-iodothyronine or liothyronine or Ltriiodothyronine or T3 or LT3).ti,ab.   |
| 38. | Tertroxin.ti,ab.   |
| 39. | "Thyroid (USP)"/   |
| 40. | ((thyroid or hormone*) adj2 (natural or desiccated or extract* or preparation*)).ti,ab.  |
| 41. | ((porcine or pig) adj thyroid).ti,ab.  |
| 42. | (NDT or DTE).ti,ab.  |
| 43. | Armour.ti,ab.  |
| 44. | or/28-43   |
| 45. | 27 and 44  |
| 46. | randomized controlled trial.pt.  |
| 47. | controlled clinical trial.pt.  |
| 48. | randomi#ed.ab.   |
| 49. | placebo.ab.  |
| 50. | randomly.ab.   |
| 51. | clinical trials as topic.sh.   |
| 52. | trial.ti.  |
| 53. | or/46-52   |
| 54. | Meta-Analysis/   |
| 55. | Meta-Analysis as Topic/  |
| 56. | (meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.   |
| 57. | ((systematic* or evidence*) adj3 (review* or overview*)).ti,ab.  |
| 58. | (reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.   |
| 59. | (search strategy or search criteria or systematic search or study selection or data extraction).ab.  |
| 60. | (search* adj4 literature).ab.  |
| 61. | (medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab. |
| 62. | cochrane.jw.   |
| 63. | ((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.   |
| 64. | or/54-63   |
| 65. | Epidemiologic studies/   |
| 66. | Observational study/   |
| 67. | exp Cohort studies/  |
| 68. | (cohort adj (study or studies or analys* or data)).ti,ab.  |
| 69. | ((follow up or observational or uncontrolled or non randomi#ed or epidemiologic*) adj (study or studies or data)).ti,ab.                               |
| 70. | ((longitudinal or retrospective or prospective) and (study or studies or review or analys* or cohort* or data)).ti,ab.                                 |
| 71. | Controlled Before-After Studies/   |
| 72. | Historically Controlled Study/   |
| 73. | Interrupted Time Series Analysis/  |
| 74. | (before adj2 after adj2 (study or studies or data)).ti,ab.   |

|     |   |
|-----|---|
| 75. | exp case control study/   |
| 76. | case control*.ti,ab.  |
| 77. | Cross-sectional studies/  |
| 78. | (cross sectional and (study or studies or review or analys* or cohort* or data)).ti,ab. |
| 79. | or/66-79  |
| 80. | 45 and (53 or 64 or 79)   |

### Embase (Ovid) search terms

|     |   |
|-----|---|
| 1.  | exp Thyroid Cancer/   |
| 2.  | (thyroid adj3 (cancer* or carcinom* or microcarcinoma* or tumo?r* or neoplasm* or metast* or adenoma* or adenocarcinom* or node* or nodul* or nodal or lump* or papillar* or swollen or swell* or anaplastic or sarcoma* or cyst* or malignan*)).ti,ab. |
| 3.  | DTC.ti,ab.  |
| 4.  | ((papillar* or anaplastic) adj2 (cancer* or carcinom* or tumo?r* or neoplasm* or metast* or adenoma* or adenocarcinom* or nodul* or node* or lump*)).ti,ab.   |
| 5.  | or/1-4  |
| 6.  | letter.pt. or letter/   |
| 7.  | note.pt.  |
| 8.  | editorial.pt.   |
| 9.  | case report/ or case study/   |
| 10. | (letter or comment*).ti.  |
| 11. | (conference abstract or conference paper).pt.   |
| 12. | or/6-11   |
| 13. | randomized controlled trial/ or random*.ti,ab.  |
| 14. | 12 not 13   |
| 15. | animal/ not human/  |
| 16. | nonhuman/   |
| 17. | exp Animal Experiment/  |
| 18. | exp Experimental Animal/  |
| 19. | animal model/   |
| 20. | exp Rodent/   |
| 21. | (rat or rats or mouse or mice or rodent*).ti.   |
| 22. | or/14-21  |
| 23. | 5 not 22  |
| 24. | limit 23 to english language  |
| 25. | (exp child/ or exp pediatrics/) not (exp adult/ or exp adolescent/)   |
| 26. | 24 not 25   |
| 27. | exp Thyrotropin/  |
| 28. | (thyrotropin* or thyreotropin* or thyrotrophin* or thyrotropic).ti,ab.  |
| 29. | (thyroid stimulating adj2 hormone*).ti,ab.  |
| 30. | TSH.ti,ab.  |
| 31. | ((thyroid or hormon*) adj4 (suppress* or lower*)).ti,ab.  |
| 32. | Thyroxine/  |
| 33. | (thyroxine or thyroxin or tetraiodothyronine or levothyroxine or Lthyroxine or T4 or LT4).ti,ab.  |
| 34. | Eltroxin.ti,ab.   |
| 35. | Liothyronine/   |
| 36. | (triiodothyronine or tri-iodothyronine or liothyronine or Ltriiodothyronine or T3 or LT3).ti,ab.  |

|     |  |
|-----|--|
| 37. | Tertroxin.ti,ab.   |
| 38. | Thyroid Extract/   |
| 39. | ((thyroid or hormone*) adj2 (natural or desiccated or extract* or preparation*)).ti,ab.  |
| 40. | ((porcine or pig) adj thyroid).ti,ab.  |
| 41. | (NDT or DTE).ti,ab.  |
| 42. | Armour.ti,ab.  |
| 43. | or/27-42   |
| 44. | 26 and 43  |
| 45. | random*.ti,ab.   |
| 46. | factorial*.ti,ab.  |
| 47. | (crossover* or cross over*).ti,ab.   |
| 48. | ((doubl* or singl*) adj blind*).ti,ab.   |
| 49. | (assign* or allocat* or volunteer* or placebo*).ti,ab.   |
| 50. | crossover procedure/   |
| 51. | single blind procedure/  |
| 52. | randomized controlled trial/   |
| 53. | double blind procedure/  |
| 54. | or/45-53   |
| 55. | Systematic Review/   |
| 56. | Meta-Analysis/   |
| 57. | (meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.   |
| 58. | ((systematic* or evidence*) adj3 (review* or overview*)).ti,ab.  |
| 59. | (reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.   |
| 60. | (search strategy or search criteria or systematic search or study selection or data extraction).ab.  |
| 61. | (search* adj4 literature).ab.  |
| 62. | (medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab. |
| 63. | cochrane.jw.   |
| 64. | ((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.   |
| 65. | or/55-64   |
| 66. | Clinical study/  |
| 67. | Observational study/   |
| 68. | Family study/  |
| 69. | Longitudinal study/  |
| 70. | Retrospective study/   |
| 71. | Prospective study/   |
| 72. | Cohort analysis/   |
| 73. | Follow-up/   |
| 74. | cohort*.ti,ab.   |
| 75. | 74 and 75  |
| 76. | (cohort adj (study or studies or analys* or data)).ti,ab.  |
| 77. | ((follow up or observational or uncontrolled or non randomi#ed or epidemiologic*) adj (study or studies or data)).ti,ab.                               |
| 78. | ((longitudinal or retrospective or prospective) and (study or studies or review or analys* or cohort* or data)).ti,ab.                                 |
| 79. | (before adj2 after adj2 (study or studies or data)).ti,ab.   |
| 80. | exp case control study/  |

|     |   |
|-----|---|
| 81. | case control*.ti,ab.  |
| 82. | cross-sectional study/  |
| 83. | (cross sectional and (study or studies or review or analys* or cohort* or data)).ti,ab. |
| 84. | or/67-73,76-84  |
| 85. | 44 and (54 or 65 or 84)   |

### **Cochrane Library (Wiley) search terms**

|      |   |
|------|---|
| #1.  | MeSH descriptor: [Thyroid Neoplasms] explode all trees  |
| #2.  | (thyroid near/3 (cancer* or carcinom* or microcarcinoma* or tumo?* or neoplasm* or metast* or adenoma* or adenocarcinom* or node* or nodul* or nodal or lump* or papillar* or swollen or swell* or anaplastic or sarcoma* or cyst* or malignan*)):ti,ab |
| #3.  | DTC:ti,ab   |
| #4.  | ((papillar* or anaplastic) near/2 (cancer* or carcinom* or tumo?* or neoplasm* or metast* or adenoma* or adenocarcinom* or nodul* or node* or lump*)):ti,ab   |
| #5.  | #1 or #2 or #3 or #4  |
| #6.  | MeSH descriptor: [Thyrotropin] explode all trees  |
| #7.  | (thyrotropin* or thyreotropin* or thyrotrophin* or thyrotropic):ti,ab   |
| #8.  | (thyroid stimulating near/2 hormone*):ti,ab   |
| #9.  | TSH:ti,ab   |
| #10. | ((thyroid or hormon*) near/4 (suppress* or lower*)):ti,ab   |
| #11. | MeSH descriptor: [Thyroxine] this term only   |
| #12. | (thyroxine or thyroxin or tetraiodothyronine or levothyroxine or Lthyroxine or T4 or LT4):ti,ab   |
| #13. | Eltroxin:ti,ab  |
| #14. | MeSH descriptor: [Triiodothyronine] this term only  |
| #15. | (triiodothyronine or tri-iodothyronine or liothyronine or Ltriiodothyronine or T3 or LT3):ti,ab   |
| #16. | Tertroxin:ti,ab   |
| #17. | MeSH descriptor: [Thyroid (USP)] this term only   |
| #18. | ((thyroid or hormone*) near/2 (natural or desiccated or extract* or preparation*)):ti,ab  |
| #19. | ((porcine or pig) next thyroid):ti,ab   |
| #20. | (NDT or DTE):ti,ab  |
| #21. | Armour:ti,ab  |
| #22. | #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21  |
| #23. | #5 and #22  |
| #24. | conference:pt or (clinicaltrials or trialsearch):so   |
| #25. | #23 not #24   |

## **Health Economics literature search strategy**

Health economic evidence was identified by conducting searches using terms for a broad Thyroid Cancer population. The following databases were searched: NHS Economic Evaluation Database (NHS EED - this ceased to be updated after 31st March 2015), Health Technology Assessment database (HTA - this ceased to be updated from 31st March 2018) and The International Network of Agencies for Health Technology Assessment (INAHTA). Searches for recent evidence were run on Medline and Embase from 2014 onwards for health economics, and all years for quality-of-life studies.

**Table 8: Database parameters, filters and limits applied**

| Database   | Dates searched  | Search filters and limits applied  |
|--|---|--|
| Medline (OVID)   | Health Economics<br>1 January 2014 – 16 December 2021 | Health economics studies<br>Quality of life studies  |
|  | Quality of Life<br>1946 – 16 December 2021            | Exclusions (animal studies, letters, comments, editorials, case studies/reports, conference abstracts)<br><br>English language |
| Embase (OVID)  | Health Economics<br>1 January 2014 – 16 December 2021 | Health economics studies<br>Quality of life studies  |
|  | Quality of Life<br>1974 – 16 December 2021            | Exclusions (animal studies, letters, comments, editorials, case studies/reports, conference abstracts)<br><br>English language |
| NHS Economic Evaluation Database (NHS EED)<br>(Centre for Research and Dissemination - CRD)  | Inception –31 <sup>st</sup> March 2015                |  |
| Health Technology Assessment Database (HTA)<br>(Centre for Research and Dissemination – CRD) | Inception – 31 <sup>st</sup> March 2018               |  |
| The International Network of Agencies for Health Technology Assessment (INAHTA)              | Inception - 16 December 2021                          | English language   |

**Medline (Ovid) search terms**

|     |  |
|-----|--|
| 1.  | exp Thyroid Neoplasms/   |
| 2.  | (thyroid adj4 (cancer* or carcinom* or tumo?* or neoplasm* or metast* or adenoma* or adenocarcinom* or nod* or lump* or papillar* or follicul* or lymphoma* or anaplastic)).ti,ab.     |
| 3.  | ((papillar* or follicul* or medullary or anaplastic) adj4 (cancer* or carcinom* or tumo?* or neoplasm* or metast* or adenoma* or adenocarcinom* or nod* or lump* or lymphoma*)).ti,ab. |
| 4.  | or/1-3   |
| 5.  | letter/  |
| 6.  | editorial/   |
| 7.  | news/  |
| 8.  | exp historical article/  |
| 9.  | Anecdotes as Topic/  |
| 10. | comment/   |
| 11. | case report/   |
| 12. | (letter or comment*).ti.   |
| 13. | or/5-12  |

|     |  |
|-----|--|
| 14. | randomized controlled trial/ or random*.ti,ab.   |
| 15. | 13 not 14  |
| 16. | animals/ not humans/   |
| 17. | exp Animals, Laboratory/   |
| 18. | exp Animal Experimentation/  |
| 19. | exp Models, Animal/  |
| 20. | exp Rodentia/  |
| 21. | (rat or rats or mouse or mice).ti.   |
| 22. | or/15-21   |
| 23. | 4 not 22   |
| 24. | limit 23 to english language   |
| 25. | economics/   |
| 26. | value of life/   |
| 27. | exp "costs and cost analysis"/   |
| 28. | exp Economics, Hospital/   |
| 29. | exp Economics, medical/  |
| 30. | Economics, nursing/  |
| 31. | economics, pharmaceutical/   |
| 32. | exp "Fees and Charges"/  |
| 33. | exp budgets/   |
| 34. | budget*.ti,ab.   |
| 35. | cost*.ti.  |
| 36. | (economic* or pharmaco?economic*).ti.  |
| 37. | (price* or pricing*).ti,ab.  |
| 38. | (cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. |
| 39. | (financ* or fee or fees).ti,ab.  |
| 40. | (value adj2 (money or monetary)).ti,ab.  |
| 41. | or/25-40   |
| 42. | 24 and 41  |
| 43. | quality-adjusted life years/   |
| 44. | sickness impact profile/   |
| 45. | (quality adj2 (wellbeing or well being)).ti,ab.  |
| 46. | sickness impact profile.ti,ab.   |
| 47. | disability adjusted life.ti,ab.  |
| 48. | (qal* or qtime* or qwb* or daly*).ti,ab.   |
| 49. | (euroqol* or eq5d* or eq 5*).ti,ab.  |
| 50. | (qol* or hql* or hqol* or h qol* or hrqol* or hr qol*).ti,ab.                                    |
| 51. | (health utility* or utility score* or disutilit* or utility value*).ti,ab.                       |
| 52. | (hui or hui1 or hui2 or hui3).ti,ab.   |
| 53. | (health* year* equivalent* or hye or hyes).ti,ab.  |
| 54. | discrete choice*.ti,ab.  |
| 55. | rosser.ti,ab.  |
| 56. | (willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab.        |
| 57. | (sf36* or sf 36* or short form 36* or shortform 36* or shortform36*).ti,ab.                      |
| 58. | (sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.                           |
| 59. | (sf12* or sf 12* or short form 12* or shortform 12* or shortform12*).ti,ab.                      |
| 60. | (sf8* or sf 8* or short form 8* or shortform 8* or shortform8*).ti,ab.                           |

|     |  |
|-----|--|
| 61. | (sf6* or sf 6* or short form 6* or shortform 6* or shortform6*).ti,ab. |
| 62. | or/52-70   |
| 63. | 24 and 62  |

### Embase (Ovid) search terms

|     |   |
|-----|---|
| 1.  | exp Thyroid Cancer/   |
| 2.  | (thyroid adj4 (cancer* or carcinom* or tumo?r* or neoplasm* or metast* or adenoma* or adenocarcinom* or nod* or lump* or papillar* or follicul* or lymphoma* or anaplastic)).ti,ab.     |
| 3.  | ((papillar* or follicul* or medullary or anaplastic) adj4 (cancer* or carcinom* or tumo?r* or neoplasm* or metast* or adenoma* or adenocarcinom* or nod* or lump* or lymphoma*)).ti,ab. |
| 4.  | or/1-3  |
| 5.  | letter.pt. or letter/   |
| 6.  | note.pt.  |
| 7.  | editorial.pt.   |
| 8.  | case report/ or case study/   |
| 9.  | (letter or comment*).ti.  |
| 10. | or/5-9  |
| 11. | randomized controlled trial/ or random*.ti,ab.  |
| 12. | 10 not 11   |
| 13. | animal/ not human/  |
| 14. | nonhuman/   |
| 15. | exp Animal Experiment/  |
| 16. | exp Experimental Animal/  |
| 17. | animal model/   |
| 18. | exp Rodent/   |
| 19. | (rat or rats or mouse or mice).ti.  |
| 20. | or/12-19  |
| 21. | 4 not 20  |
| 22. | limit 21 to english language  |
| 23. | health economics/   |
| 24. | exp economic evaluation/  |
| 25. | exp health care cost/   |
| 26. | exp fee/  |
| 27. | budget/   |
| 28. | funding/  |
| 29. | budget*.ti,ab.  |
| 30. | cost*.ti.   |
| 31. | (economic* or pharmaco?economic*).ti.   |
| 32. | (price* or pricing*).ti,ab.   |
| 33. | (cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.  |
| 34. | (financ* or fee or fees).ti,ab.   |
| 35. | (value adj2 (money or monetary)).ti,ab.   |
| 36. | or/23-35  |
| 37. | 22 and 36   |
| 38. | quality-adjusted life years/  |
| 39. | "quality of life index"/  |

|     |   |
|-----|---|
| 40. | short form 12/ or short form 20/ or short form 36/ or short form 8/                       |
| 41. | sickness impact profile/  |
| 42. | (quality adj2 (wellbeing or well being)).ti,ab.   |
| 43. | sickness impact profile.ti,ab.  |
| 44. | disability adjusted life.ti,ab.   |
| 45. | (qal* or qtime* or qwb* or daly*).ti,ab.  |
| 46. | (euroqol* or eq5d* or eq 5*).ti,ab.   |
| 47. | (qol* or hqi* or hqi* or h qol* or hrqol* or hr qol*).ti,ab.                              |
| 48. | (health utility* or utility score* or disutilit* or utility value*).ti,ab.                |
| 49. | (hui or hui1 or hui2 or hui3).ti,ab.  |
| 50. | (health* year* equivalent* or hye or hyes).ti,ab.   |
| 51. | discrete choice*.ti,ab.   |
| 52. | rosser.ti,ab.   |
| 53. | (willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab. |
| 54. | (sf36* or sf 36* or short form 36* or shortform 36* or shortform36*).ti,ab.               |
| 55. | (sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.                    |
| 56. | (sf12* or sf 12* or short form 12* or shortform 12* or shortform12*).ti,ab.               |
| 57. | (sf8* or sf 8* or short form 8* or shortform 8* or shortform8*).ti,ab.                    |
| 58. | (sf6* or sf 6* or short form 6* or shortform 6* or shortform6*).ti,ab.                    |
| 59. | or/37-58  |
| 60. | 22 and 59   |

#### **NHS EED and HTA (CRD) search terms**


|     |  |
|-----|--|
| #1. | MeSH DESCRIPTOR Thyroid Neoplasms EXPLODE ALL TREES  |
| #2. | ((thyroid NEAR4 (cancer* or carcinom* or tumour* or tumor* or neoplasm* or metast* or adenoma* or adenocarcinom* or nod* or lump* or papillar* or follicul* or lymphoma* or anaplastic)))      |
| #3. | ((((papillar* or follicul* or medullary or anaplastic) NEAR4 (cancer* or carcinom* or tumour* or tumor* or neoplasm* or metast* or adenoma* or adenocarcinom* or nod* or lump* or lymphoma*))) |
| #4. | #1 OR #2 OR #3   |

#### **NHATA search terms**

|    |  |
|----|--|
| 1. | (Thyroid Neoplasms)[mh] OR (thyroid neoplasms) AND (thyroid cancers) |
|----|--|

## Appendix C – Effectiveness evidence study selection

Figure 1: Flow chart of clinical study selection for the review of Levothyroxine TSH suppression vs no additional suppression



## Appendix D – Effectiveness evidence

| Study                                       | Abo-touk 2015 <sup>1</sup>  |
|---|---|
| Study type                                  | RCT (Patient randomised; Parallel)  |
| Number of studies (number of participants)  | n/a (n=148)   |
| Countries and setting                       | Conducted in Egypt; Setting: Department of clinical oncology and nuclear medicine, faculty of medicine, Mansoura University, Egypt  |
| Line of therapy                             | 3rd line  |
| Duration of study                           | Intervention + follow up: up to 86 months   |
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis   |
| Stratum                                     | Other – mixed   |
| Subgroup analysis within study              | Not applicable  |
| Inclusion criteria                          | Patients aged from 18 - 70 with pathologically confirmed operable differentiated thyroid carcinoma who presented to the department during November 2006 and December 2010. All patients were aimed to be treated with total or near total thyroidectomy and lymph node surgery was performed according to their presentation. |
| Exclusion criteria                          | Patients with a maximum diameter or primary tumour 1cm or smaller (microcarcinoma) as measured by preoperative ultrasonography or postoperative data, distant metastasis, grave's disease, ischemic heart disease or arrhythmia, or severe osteoporosis were excluded.  |
| Recruitment/selection of patients           | Patients aged from 18 - 70 with pathologically confirmed operable differentiated thyroid carcinoma who presented to the department during the study period  |
| Age, gender and ethnicity                   | Age - Other: <45: 96; ≥45: 52. Gender (M:F): 30/118. Ethnicity: n/a   |

|   |   |
|---|---|
| Further population details  |   |
| Indirectness of population  | No indirectness   |
| Interventions   | <p>(n=76) Intervention 1: TSH suppression - high dose Levothyroxine (T4). TSH suppression therapy - L-T4 was given at an initial dose of 100µg/d for patients with body weight under 50kg, 150 µg/d for patients weighting 50-70kg and 200µg/d for patients weighing 70kg or more. Serum levels of free T4, free T3 and TSH were done every 4 weeks. The daily dose of LT4 is then adjusted in the patients of this group to suppression TSH levels below 0.1µU/ml. Duration of study (Nov 2006 - December 2010). Concurrent medication/care: daily intake of calcium (1200mg/day) and vitamin D (1000 units/day). Postoperatively radioiodine therapy was given when the patient with a completely resected tumour had a significant potential for recurrence. Patients were treated with about 50 - 100 mCi of radioiodine. In case of incomplete tumour resection, 150 - 200 mCi was administered. . Indirectness: No indirectness<br/>Further details: 1. Duration of TSH supplementation: 2. Level of TSH suppression:<br/>Comments: Ames risk of recurrence: Low - 26; high - 50</p> <p>(n=72) Intervention 2: No TSH suppression - No additional TSH suppression. TSH suppression therapy - L-T4 was given at an initial dose of 100µg/d for patients with body weight under 50kg, 150 µg/d for patients weighting 50-70kg and 200µg/d for patients weighing 70kg or more. Serum levels of free T4, free T3 and TSH were done every 4 weeks. The daily dose of LT4 is then adjusted in the patients of this group to normal range (0.27 - 4.2 µU/ml). Duration of study (Nov 2006 - December 2010). Concurrent medication/care: daily intake of calcium (1200mg/day) and vitamin D (1000 units/day). Postoperatively radioiodine therapy was given when the patient with a completely resected tumour had a significant potential for recurrence. Patients were treated with about 50 - 100 mCi of radioiodine. In case of incomplete tumour resection, 150 - 200 mCi was administered. Indirectness: No indirectness<br/>Further details: 1. Duration of TSH supplementation: 2. Level of TSH suppression:<br/>Comments: Ames risk of recurrence: low - 30; high - 42</p> |
| Funding   | Funding not stated  |
| <p><b>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: HIGH DOSE LEVOTHYROXINE (T4) versus NO ADDITIONAL TSH SUPPRESSION</b></p> <p>Protocol outcome 1: mortality at Define<br/>- Actual outcome for Other - mixed: Mortality at 54 months; Group 1: 2/76, Group 2: 6/72<br/>Risk of bias: All domain – Very high, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover -</p> |   |

Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 2: cancer recurrence at Define

- Actual outcome for Other - mixed: Cancer recurrence at 54 months; Group 1: 6/76, Group 2: 13/72


Risk of bias: All domain – Very high, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0

|   |  |
|---|--|
| Protocol outcomes not reported by the study | Quality of life at Define; Thyroglobulin levels at Define; local cancer progression at Define; Incidence of distant metastases at Define; Osteoporosis at Define; Cardiac complications at Define; second primary malignancy at Define |
|---|--|


## Appendix E – Forest plots

### E.1 Levothyroxine suppression vs no additional suppression

**Figure 2: Cancer recurrence**



**Figure 3: Mortality**



## Appendix F – GRADE tables


**Table 9: Clinical evidence profile: Levothyroxine suppression vs no additional suppression**

| Quality assessment                                |                   |                           |                          |                         |                           |                      | No of patients |                           | Effect                 |  | Quality          | Importance |
|---|-------------------|---------------------------|--------------------------|-------------------------|---------------------------|----------------------|----------------|---------------------------|------------------------|--|------------------|------------|
| No of studies                                     | Design            | Risk of bias              | Inconsistency            | Indirectness            | Imprecision               | Other considerations | T4 suppression | No additional suppression | Relative (95% CI)      | Absolute                                       |                  |            |
| <b>Cancer Recurrence (follow-up 24-86 months)</b> |                   |                           |                          |                         |                           |                      |                |                           |                        |  |                  |            |
| 1   | randomised trials | Very serious <sup>1</sup> | no serious inconsistency | no serious indirectness | serious <sup>2</sup>      | none                 | 6/76 (7.9%)    | 18.1%                     | RR 0.44 (0.18 to 1.09) | 101 fewer per 1000 (from 148 fewer to 16 more) | ⊕⊕○○<br>VERY LOW | CRITICAL   |
| <b>Mortality (follow-up 24-86 months)</b>         |                   |                           |                          |                         |                           |                      |                |                           |                        |  |                  |            |
| 1   | randomised trials | Very serious <sup>1</sup> | no serious inconsistency | no serious indirectness | very serious <sup>2</sup> | none                 | 2/76 (2.6%)    | 8.3%                      | RR 0.32 (0.07 to 1.51) | 38 fewer per 1000 (from 52 fewer to 29 more)   | ⊕○○○<br>VERY LOW | CRITICAL   |

<sup>1</sup> Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

<sup>2</sup> Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

## Appendix G – Economic evidence study selection



\* Non-relevant population, intervention, comparison, design or setting; non-English language

## **Appendix H – Economic evidence tables**

None.

## Appendix I – Excluded studies

### I.1 Clinical studies

**Table 10: Studies excluded from the clinical review**

| Reference                                      | Reason for exclusion  |
|--|---|
| Anonymous 2018 <sup>26</sup>                   | Paper not in English  |
| Ahmed 2013 <sup>2</sup>                        | Incorrect study design – objective to determine correct dose of Levothyroxine according to lean body mass |
| Akirov 2019 <sup>3</sup>                       | Systematic Review – references checked  |
| Almodovar Ruiz 2000 <sup>4</sup>               | Paper not in English  |
| Appelhof 2005 <sup>5</sup>                     | Incorrect population – primary autoimmune hypothyroid (thyroidectomy excluded)                            |
| Boguszewski 1998 <sup>6</sup>                  | Incorrect population – patients with palpable thyroid nodule only   |
| Brancatella 2020 <sup>7</sup>                  | Literature review – references checked  |
| Brun 2021 <sup>8</sup>                         | Incorrect study design – validation study to determine dosage of Levothyroxine, no relevant outcomes.     |
| Bunevicius 2002 <sup>9</sup>                   | Incorrect population – Grave's disease  |
| Bunevicius 1997 <sup>10</sup>                  | Paper not available   |
| Bunevicius 1998 <sup>11</sup>                  | Paper not available   |
| Bunevicius 2000 <sup>12</sup>                  | Incorrect study design – cross over study   |
| Burgos 2020 <sup>13</sup>                      | Incorrect study design – investigating side effects of discontinuing TSH suppression                      |
| Celi 2010 <sup>15</sup>                        | Incorrect study design – cross over study   |
| Clyde 2003 <sup>16</sup>                       | Incorrect population – only one participant with thyroid cancer   |
| Eustatia-Rutten 2006 <sup>17</sup>             | Incorrect study design – follow up period too short (6 months)  |
| Faber 1994 <sup>18</sup>                       | Incorrect study design – cross sectional observational study  |
| Fischman 2018 <sup>19</sup>                    | Paper not in English  |
| Fussey 2017 <sup>20</sup>                      | Literature review – references checked  |
| Greenspan 1999 <sup>21</sup>                   | Systematic Review – references checked  |
| Helfand 1990 <sup>23</sup>                     | Literature review – references checked  |
| Hennessey 2018 <sup>24</sup>                   | Literature review – references checked  |
| Iakovou 2010 <sup>25</sup>                     | Incorrect study design – case control study   |
| Lee 2021 <sup>28</sup>                         | Incorrect study design – study protocol only  |
| Lee, 2021 <sup>29</sup>                        | Non-randomised  |
| Lee 2019 <sup>30</sup>                         | Systematic Review – references checked  |
| Ma 2009 <sup>31</sup>                          | Systematic Review – references checked  |
| Mendonca Monteiro de Barros 2016 <sup>32</sup> | Incorrect study design – cross sectional observational study  |
| Quan 2002 <sup>33</sup>                        | Systematic Review – references checked  |
| Regalbuto 2007 <sup>34</sup>                   | Incorrect study design – cohort study (no discussion or clarity on randomization)                         |
| Saravanan 2005 <sup>35</sup>                   | Incorrect population – participants with thyroid cancer were excluded                                     |
| Schaffler 2010 <sup>36</sup>                   | Literature review – references checked  |
| Sugitani 2010 <sup>37</sup>                    | Incorrect population – participants did not undergo RAI treatment   |
| Sugitani 2011 <sup>38</sup>                    | Incorrect population – participants did not undergo RAI treatment   |

| Reference                      | Reason for exclusion   |
|--------------------------------|--|
| Valle 2013 <sup>39</sup>       | No relevant outcomes – objective of study to determine dosages for TSH suppression cut off point |
| van Vliet 2018 <sup>40</sup>   | Incorrect study design – cohort study investigating gene association                             |
| Vera 2016 <sup>41</sup>        | Incorrect study design – case control study  |
| Vestergaard 2005 <sup>42</sup> | Incorrect study design – case control study  |
| Wang 2020 <sup>43</sup>        | Systematic Review – references checked   |
| Yamazaki 2012 <sup>44</sup>    | Incorrect study design – investigating lithium adjuvant post thyroidectomy                       |
| Yoon 2019 <sup>45</sup>        | Systematic Review – references checked   |

## I.2 Health Economic studies

Published health economic studies that met the inclusion criteria (relevant population, comparators, economic study design, published 2005 or later and not from non-OECD country or USA) but that were excluded following appraisal of applicability and methodological quality are listed below. See the health economic protocol for more details.